Related Experiment Video
Updated: Jul 17, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
RNA Sequencing and Bioinformatics Analysis Reveals the Downregulation of DNA Replication Genes by Morindone in
Cheok Wui Chee1, Najihah Mohd Hashim2,3,4, Iskandar Abdullah4,5
1Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Abstract:
Morindone, a natural anthraquinone compound, has been reported to have significant pharmacological properties in different cancers. However, its anticancer effects in colorectal cancer (CRC) and the underlying molecular mechanisms remain obscure. In this study, RNA sequencing was used to assess the differentially expressed genes (DEGs) following morindone treatment in two CRC cell lines, HCT116 and HT29 cells. Functional enrichment analysis of overlapping DEGs revealed that negative regulation of cell development from biological processes and the MAPK signalling pathway were the most significant Gene Ontology terms and Kyoto Encyclopaedia of Genes and Genome pathway, respectively. Seven hub genes were identified among the overlapping genes, including MCM5, MCM6, MCM10, GINS2, POLE2, PRIM1, and WDHD1. All hub genes were found downregulated and involved in DNA replication fork. Among these, GINS2 was identified as the most cancer-dependent gene in both cells with better survival outcomes. Validation was performed on seven hub genes with rt-qPCR, and the results were consistent with the RNA sequencing findings. Collectively, this study provides corroboration of the potential therapeutic benefits and suitable pharmacological targets of morindone in the treatment of CRC.
Insights
Morindone shows potential against colorectal cancer (CRC) by downregulating key DNA replication genes. This study identifies GINS2 as a promising therapeutic target for CRC treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Morindone, a natural anthraquinone, exhibits pharmacological properties in various cancers.
- Anticancer effects and molecular mechanisms of morindone in colorectal cancer (CRC) are not well understood.
Purpose of the Study:
- To investigate the anticancer effects of morindone in colorectal cancer (CRC) cell lines.
- To elucidate the molecular mechanisms underlying morindone's action in CRC using RNA sequencing.
Main Methods:
- RNA sequencing was employed to identify differentially expressed genes (DEGs) in HCT116 and HT29 CRC cells after morindone treatment.
- Functional enrichment analysis (Gene Ontology and Kyoto Encyclopaedia of Genes and Genomes) was performed on overlapping DEGs.
- Seven hub genes were identified and validated using reverse transcription quantitative polymerase chain reaction (rt-qPCR).
Main Results:
- Morindone treatment led to the downregulation of seven hub genes (MCM5, MCM6, MCM10, GINS2, POLE2, PRIM1, WDHD1) involved in DNA replication.
- The most significant functional enrichments included negative regulation of cell development and the MAPK signaling pathway.
- GINS2 was identified as the most cancer-dependent gene, correlating with better survival outcomes in both cell lines.
Conclusions:
- Morindone demonstrates potential therapeutic benefits for colorectal cancer (CRC).
- The study identifies key DNA replication genes, particularly GINS2, as potential pharmacological targets for morindone-based CRC therapy.
- Findings provide a foundation for further investigation into morindone as a CRC treatment.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
The DNA Replication Fork
Restarting Stalled Replication Forks

